Jonathan Tosh

1.8k total citations · 1 hit paper
41 papers, 1.3k citations indexed

About

Jonathan Tosh is a scholar working on Economics and Econometrics, Rheumatology and Hematology. According to data from OpenAlex, Jonathan Tosh has authored 41 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Economics and Econometrics, 14 papers in Rheumatology and 7 papers in Hematology. Recurrent topics in Jonathan Tosh's work include Rheumatoid Arthritis Research and Therapies (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Jonathan Tosh is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Jonathan Tosh collaborates with scholars based in United Kingdom, United States and Germany. Jonathan Tosh's co-authors include Louise Longworth, John Brazier, Mónica Hernández Alava, Philippa Evans, Allan Wailoo, Aki Tsuchiya, Clara Mukuria, Tracey Young, Chris Deighton and Pippa Evans and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American College of Cardiology and Annals of the Rheumatic Diseases.

In The Last Decade

Jonathan Tosh

38 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey

2014 335 citations Louise Longworth, Mónica Hernández Alava et al. Health Technology Assessment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Tosh United Kingdom	17	540	311	243	192	141	41	1.3k
Anita Burrell United States	9	383 0.7×	140 0.5×	129 0.5×	89 0.5×	112 0.8×	22	2.0k
Isao Kamae Japan	20	273 0.5×	514 1.7×	110 0.5×	68 0.4×	80 0.6×	69	1.6k
Eleanor M. Perfetto United States	17	399 0.7×	150 0.5×	278 1.1×	80 0.4×	64 0.5×	81	1.3k
Thomas Mittendorf Germany	23	465 0.9×	441 1.4×	248 1.0×	160 0.8×	99 0.7×	105	1.7k
Ross Maclean United States	20	282 0.5×	811 2.6×	255 1.0×	397 2.1×	194 1.4×	38	1.6k
Jörg Ruof Germany	21	401 0.7×	635 2.0×	160 0.7×	188 1.0×	97 0.7×	67	1.4k
Catherine Copley‐Merriman United States	22	469 0.9×	54 0.2×	207 0.9×	87 0.5×	64 0.5×	68	1.7k
S Vasoo Singapore	15	167 0.3×	313 1.0×	69 0.3×	75 0.4×	55 0.4×	29	915
Marco Barbieri United Kingdom	14	524 1.0×	139 0.4×	247 1.0×	64 0.3×	36 0.3×	34	1.1k
Annette de Thurah Denmark	24	124 0.2×	882 2.8×	240 1.0×	420 2.2×	232 1.6×	99	1.8k

Countries citing papers authored by Jonathan Tosh

Since Specialization

Citations

This map shows the geographic impact of Jonathan Tosh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Tosh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Tosh more than expected).

Fields of papers citing papers by Jonathan Tosh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Tosh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Tosh. The network helps show where Jonathan Tosh may publish in the future.

Co-authorship network of co-authors of Jonathan Tosh

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Tosh. A scholar is included among the top collaborators of Jonathan Tosh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Tosh. Jonathan Tosh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Mo, et al.. (2022). Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping. Value in Health. 26(4). 487–497. 2 indexed citations

Tosh, Jonathan, Cosmina Hogea, Yevgeniy Samyshkin, et al.. (2021). Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. ClinicoEconomics and Outcomes Research. Volume 13. 789–800.

Crown, William H., Nasuh Büyükkaramikli, Mustafa Y. Sır, et al.. (2018). Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health. 21(9). 1019–1028. 30 indexed citations

Mamas, Mamas, Jonathan Tosh, William Hulme, et al.. (2017). TCT-434 Economic benefits of transradial percutaneous coronary intervention; a national analysis from the British Cardiovascular Intervention Society database. Journal of the American College of Cardiology. 70(18). B178–B178. 2 indexed citations

Stevenson, Matt, Allan Wailoo, Jonathan Tosh, et al.. (2017). The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. The Journal of Rheumatology. 44(7). 973–980. 16 indexed citations

Crown, William H., Nasuh Büyükkaramikli, Praveen Thokala, et al.. (2017). Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health. 20(3). 310–319. 76 indexed citations

Martin, Naomi, Fowzia Ibrahim, Brian D. M. Tom, et al.. (2017). Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. Trials. 18(1). 591–591. 15 indexed citations

Stevenson, Matt, Rachel Archer, Jonathan Tosh, et al.. (2016). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment. 20(35). 1–610. 116 indexed citations

Tosh, Jonathan, Matt Stevenson, R. Akehurst, & Mark Strong. (2015). Simulation optimisation of Treatment Sequences for Rheumatoid arthritis. Value in Health. 18(7). A343–A343. 2 indexed citations

10.

Madan, Jason, A. E. Ades, Pelham Barton, et al.. (2015). Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party. Rheumatology and Therapy. 2(2). 113–125. 8 indexed citations

11.

Sampson, Chris, Jonathan Tosh, Christopher P. Cheyne, Deborah Broadbent, & Marilyn James. (2015). Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis. Systematic Reviews. 4(1). 15–15. 10 indexed citations

12.

Wailoo, Allan, Matt Stevenson, Jonathan Tosh, et al.. (2014). The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards. Value in Health. 17(7). A380–A380. 1 indexed citations

13.

Norton, Sam, Bo Fu, David L. Scott, et al.. (2014). Health Assessment Questionnaire disability progression in early rheumatoid arthritis: Systematic review and analysis of two inception cohorts. Seminars in Arthritis and Rheumatism. 44(2). 131–144. 58 indexed citations

14.

Tosh, Jonathan, Rachel Archer, Sarah Davis, Matt Stevenson, & John Stevens. (2013). Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal. PharmacoEconomics. 31(8). 653–661. 16 indexed citations

15.

Blank, Lindsay, Joanne Coster, Alicia O’Cathain, et al.. (2012). The appropriateness of, and compliance with, telephone triage decisions: a systematic review and narrative synthesis. Journal of Advanced Nursing. 68(12). 2610–2621. 73 indexed citations

16.

Saxton, John, Anouska Carter, Amanda Daley, et al.. (2012). Pragmatic exercise intervention for people with multiple sclerosis (ExIMS Trial): Study protocol for a randomised controlled trial. Contemporary Clinical Trials. 34(2). 205–211. 13 indexed citations

17.

Tosh, Jonathan, John Brazier, Philippa Evans, & Louise Longworth. (2011). A Review of Generic Preference-Based Measures of Health-Related Quality of Life in Visual Disorders. Value in Health. 15(1). 118–127. 117 indexed citations

18.

Tosh, Jonathan, Louise Longworth, & Elisabeth George. (2011). Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value in Health. 14(1). 102–109. 84 indexed citations

19.

Tosh, Jonathan, Alan Brennan, Allan Wailoo, & Nick Bansback. (2011). The Sheffield rheumatoid arthritis health economic model. Lara D. Veeken. 50(suppl 4). iv26–iv31. 22 indexed citations

20.

Deighton, Chris, et al.. (2009). Management of rheumatoid arthritis: summary of NICE guidance. BMJ. 338(mar16 1). b702–b702. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact